iBio Inc. has announced the development of an antibody targeting Activin E, a protein linked to cardiometabolic disorders and obesity. This advancement was made in partnership with AstralBio Inc. and utilizes iBio’s proprietary Machine-Learning Antibody Engine. The antibody has demonstrated strong binding to Activin E in preclinical studies, blocking the protein’s signaling, which plays a role in metabolic health regulation. This collaboration grants AstralBio an exclusive license to use iBio’s Drug Discovery (NASDAQ:WBD) Platform to engineer four targets for cardiometabolic disease treatment, with options for further preclinical development. iBio retains the option to license three cardiometabolic targets from AstralBio, with rights to develop, manufacture, and commercialize these targets. Additionally, iBio recently licensed an anti-myostatin antibody from AstralBio and developed a bispecific antibody targeting myostatin and Activin A. The companies have not disclosed specific timelines for clinical development, but the rapid progress highlights the effectiveness of iBio’s technology platform.
https://in.investing.com/news/company-news/ibio-stock-soars-to-52week-high-reaches-503-93CH-4692984
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.